Chronic Graft-Versus-Host Disease
Chronic Graft-Versus-Host Disease (cGVHD) is a complication that can occur after a stem cell or bone marrow transplant, where the donor's immune cells attack the recipient's body, leading to various symptoms.
Chronic Graft-Versus-Host Disease: Axatilimab Treatment Study
We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 12 and 75 years old?
- Do you have active, moderate to severe chronic graft-versus-host disease (cGVHD)?
- Have you had a stem cell transplant (allo-HCT) from any donor?
- Are you currently pregnant or breastfeeding?
- Have you had any systemic treatment for cGVHD in the last 2 weeks?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Axatilimab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Graz
Department of Internal Medicine, Division of Hematology
Graz, Austria
Medizinische Universitaet Innsbruck
Department of Internal Medicine V
Innsbruck, Austria
Ordensklinikum Linz GmbH
Department of Internal Medicine, Hematology and Oncology
Linz, Austria
Sponsor: Incyte Corp.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.